Profusa has entered into a distribution agreement with MedSell to commercialize its Lumee™ Oxygen tissue monitoring device in France, supplementing existing partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom and Scandinavia. This expanded network now covers approximately 200,000 critical limb ischemia (CLI) cases annually across the European Union. The French partnership complements Profusa’s collaboration with Dr. Yann Gouëffic of Groupe Hospitalier Paris Saint Joseph, whose practice represents about 8% of France’s CLTI caseload. Profusa forecasts initial European revenues of $0.5–$2 million in 2026 and $9–$13 million in 2027, with a long-term target of $200–$250 million by 2030 as it scales clinic and home monitoring applications.

On December 30, Profusa announced amendments to its Senior Secured Convertible Notes designed to enhance balance-sheet flexibility and reduce shareholder dilution. The conversion floor price was raised from $0.10 to $0.35, mandatory amortization payments due in Q1 2026 were eliminated, and mandatory equity line of credit (ELOC) payments increased from 17.5% to 33% for existing registration statements and to 50% for any new Form S-1 filings. The notes mature 18 months after issuance, with all principal due at maturity. Profusa’s CFO noted that the restructuring will free cash flow to support commercial initiatives, inventory build and strategic partnerships in early 2026.